
Holzer & Holzer, LLC is investigating whether Abivax S.A. complied with federal securities laws following a report by Scorpion Capital that criticized the drug obefazimod for high lipophilicity and potential safety concerns. The report alleged the drug fails basic oral drug viability tests and resembles harmful pollutants, causing Abivax's stock price to fall. Investors who suffered losses are encouraged to contact the law firm for possible legal action. This investigation highlights potential risks around Abivax's drug development and its impact on shareholder value.
Abivax S.A. shares are currently priced at USD 72.41 on Pluang as of Nov 21, 2026 01:51 WIB. The stock has experienced a significant 1-day decline of 10.22%, reflecting market sensitivity to recent news. Trading volume stands at 2,326,731, with investors typically holding the stock for 18 days on the platform.